Takeda And Eisai Cut U.S. Sales Force And Increase Chinese Presence
This article was originally published in PharmAsia News
Executive Summary
Facing sales avalanches due to major drug patent expirations, Japanese drug makers are cutting cost and reducing headcount in the U.S